NEXT REPORT TO BE PUBLISHED IS: CIRCULATORY AND MENTAL HEALTH - TO COMPLETE THE REPORTS IN THIS SERIES FOR 2015
SEE BELOW FOR REPORTS PUBLISHED THUS FAR IN 2016:
SEE BELOW FOR REPORTS PUBLISHED THUS FAR IN 2016:
THE CORPORATE REPUTATION OF PHARMA 2015 (NEUROLOGICAL EDITION)
- THE PATIENT PERSPECTIVE
- THE PATIENT PERSPECTIVE
The 29 companies analysed:
AbbVie I Actavis I Allergan I Amgen I AstraZeneca I Bayer I Biogen Idec I Boehringer Ingelheim I Bristol-Myers Squibb I Eisai I Grünenthal I GSK I Ipsen I Janssen I Lundbeck I Merck & Co I Merck KGaA I Mylan I Novartis I Pfizer I Roche I Sandoz I Sanofi I Servier I Shire I Takeda I Teva I UCB |
London, published April 25th, 2016. This report is based on the findings of a PatientView November 2015-January 2016 survey exploring the views of 257 neurological patient groups worldwide. The report provides feedback on the corporate reputation of the pharma industry during 2015, from the perspective of these patient groups, as well as the performance of 29 pharma companies for six key indicators that influence corporate reputation. Results are compared with those of the previous year.
The report also offers, as a case study survey responses from one Israeli company, Teva. Teva explains what they are doing on the subject of global patient centricity, and comment about their relationships with patient groups. |
THE CORPORATE REPUTATION OF PHARMA 2015 (SKIN EDITION)
- THE PATIENT PERSPECTIVE
- THE PATIENT PERSPECTIVE
The 20 companies analysed:
AbbVie I Actavis I Amgen I AstraZeneca I Bayer I Boehringer Ingelheim I Bristol-Myers Squibb I Celgene I GSK I Janssen I Leo Pharma I Lilly I Merck & Co I Novartis I Pfizer I Roche I Sandoz I Sanofi I Teva I UCB To obtain more details about this report click on links below: |
London, published May 9th, 2016. This report is based on the findings of a PatientView November 2015-January 2016 survey exploring the views of 110 patient groups with an interest in skin worldwide. The report provides feedback on the corporate reputation of the pharma industry during 2015, from the perspective of these patient groups, as well as the performance of 20 pharma companies for six key indicators that influence corporate reputation. Results are compared with those of the previous year.
The report also offers, as a case study survey responses from one Danish company, Leo Pharma. Leo Pharma explains what they are doing on the subject of global patient centricity, and comment about their relationships with patient groups. 
| ||
THE CORPORATE REPUTATION OF PHARMA 2015 (RARE DISEASE EDITION)
- THE PATIENT PERSPECTIVE
- THE PATIENT PERSPECTIVE
|
London, published May 17th, 2016. This report is based on the findings of a PatientView November 2015-January 2016 survey exploring the views of 199 patient groups with an interest in rare diseases worldwide. The report provides feedback on the corporate reputation of the pharma industry during 2015, from the perspective of these patient groups, as well as the performance of 28 pharma companies for six key indicators that influence corporate reputation. Results are compared with those of the previous year.
The 28 companies analysed:
AbbVie I Actavis I Allergan I Amgen I AstraZeneca I Baxalta I Bayer I Biogen Idec I Boehringer Ingelheim I Bristol-Myers Squibb I Celgene I Gilead I GSK I Janssen I Lilly I Lundbeck I Merck & Co I Merck KGaA I Novartis I Novo Nordisk I Pfizer I Roche I Sandoz I Sanofi I Shire I Takeda I Teva I UCB To obtain more details about this report click on links below:
| ||
THE CORPORATE REPUTATION OF PHARMA 2015 (DIABETES EDITION)
- THE PATIENT PERSPECTIVE
- THE PATIENT PERSPECTIVE
|
London, published August 8th, 2016. This report is based on the findings of a PatientView November 2015-January 2016 survey exploring the views of 139 patient groups with an interest in diabetes worldwide. The report provides feedback on the corporate reputation of the pharma industry during 2015, from the perspective of these patient groups, as well as the performance of 21 pharma companies for six key indicators that influence corporate reputation. Results are compared with those of the previous year.
The 21 companies analysed:
AbbVie I Actavis I Amgen I AstraZeneca I Bayer I Boehringer Ingelheim I Bristol-Myers Squibb I Eli Lilly (Lilly) I GSK I Janssen I Menarini I Merck & Co I Novartis I Novo Nordisk I Pfizer I Roche I Sandoz I Sanofi I Servier I Takeda I Teva To obtain more details about this report click on links below:
|
| ||
THE CORPORATE REPUTATION OF PHARMA 2015 (HEPATITIS EDITION)
- THE PATIENT PERSPECTIVE
- THE PATIENT PERSPECTIVE
To read more details about this report click on the link below:
http://createsend.com/t/j-3026B6FBD2FC6604 |
London, published August 24th, 2016. This report is based on the findings of a PatientView November 2015-January 2016 survey exploring the views of 111 patient groups with an interest in hepatitis worldwide. The report provides feedback on the corporate reputation of the pharma industry during 2015, from the perspective of these patient groups, as well as the performance of 14 pharma companies for six key indicators that influence corporate reputation. Results are compared with those attained across all therapy areas in 2015.
The 14 companies analysed:
AbbVie I Bayer I Boehringer Ingelheim I Bristol-Myers Squibb I Gilead Sciences I GSK I Janssen I Merck & Co I Novartis I Pfizer I Roche I Sandoz I Sanofi I ViiV healthcare To obtain more details about this report click on links below:
| ||
THE CORPORATE REPUTATION OF PHARMA 2015 (HIV/AIDS EDITION)
- THE PATIENT PERSPECTIVE
- THE PATIENT PERSPECTIVE
|
London, published September 5th 2016. This report is based on the findings of a PatientView November 2015-January 2016 survey exploring the views of 107 patient groups with an interest in HIV/AIDS worldwide. The report provides feedback on the corporate reputation of the pharma industry during 2015, from the perspective of these patient groups, as well as the performance of 12 pharma companies for six key indicators that influence corporate reputation. Results are compared with those attained across all therapy areas in 2015.
The 12 companies analysed:
AbbVie I Boehringer Ingelheim I Bristol-Myers Squibb I Gilead Sciences I GSK I Janssen I Merck & Co I Novartis I Pfizer I Roche I Sanofi I ViiV healthcare To obtain more details about this report click on links below:
|
| ||
THE CORPORATE REPUTATION OF PHARMA 2015 (CANCER EDITION)
- THE PATIENT PERSPECTIVE
- THE PATIENT PERSPECTIVE
|
London, published 18th October 2016. This report is based on the findings of a PatientView November 2015-January 2016 survey exploring the views of 280 patient groups with an interest in cancer worldwide. The report provides feedback on the corporate reputation of the pharma industry during 2015, from the perspective of these patient groups, as well as the performance of 31 pharma companies for six key indicators that influence corporate reputation. Results are compared with those attained across all therapy areas in 2015.
The 31 companies analysed:
AbbVie I Amgen I Astellas I AstraZeneca I Baxalta I Bayer I Biogen Idec I Boehringer Ingelheim I Bristol-Myers Squibb I Celgene I Eisai I Eli Lilly (Lilly) I Ferring I Gilead Sciences I Grünenthal I GSK I Ipsen I Janssen I Leo Pharma I Lundbeck I Merck & Co I Merck KGaA I Novartis I Pfizer I Roche I Sandoz I Sanofi I Servier I Shire I Takeda I Teva To obtain more details about this report click on links below:
| ||
THE CORPORATE REPUTATION OF PHARMA 2015 (RESPIRATORY EDITION)
- THE PATIENT PERSPECTIVE
- THE PATIENT PERSPECTIVE
|
London, published 27th October 2016. This report is based on the findings of a PatientView November 2015-January 2016 survey exploring the views of 118 patient groups with an interest in respiratory conditions worldwide. The report provides feedback on the corporate reputation of the pharma industry during 2015, from the perspective of these patient groups, as well as the performance of 15 pharma companies for six key indicators that influence corporate reputation. Results are compared with those attained across all therapy areas in 2015.
The 15 companies analysed:
AbbVie I Amgen I AstraZeneca I Bayer I Boehringer Ingelheim I Eli Lilly (Lilly) I GSK I Janssen I Merck & Co I Novartis I Pfizer I Roche I Sandoz I Sanofi I Teva To obtain more details about this report click on links below:
|
| ||
THE CORPORATE REPUTATION OF PHARMA 2015 (CIRCULATORY EDITION)
- THE PATIENT PERSPECTIVE
- THE PATIENT PERSPECTIVE
|
London, to be published 7th November 2016. This report is based on the findings of a PatientView November 2015-January 2016 survey exploring the views of 90 patient groups with an interest in heart and circulatory conditions worldwide. The report provides feedback on the corporate reputation of the pharma industry during 2015, from the perspective of these patient groups, as well as the performance of 15 pharma companies for six key indicators that influence corporate reputation. Results are compared with those attained across all therapy areas in 2015.
The 15 companies analysed:
AbbVie I Amgen I AstraZeneca I Bayer I Boehringer Ingelheim I Bristol Myers-Squibb I Eli Lilly (Lilly) I GSK I Janssen I Merck & Co I Novartis I Pfizer I Roche I Sandoz I Sanofi To obtain more details about this report click on links below:
|
| ||
THE CORPORATE REPUTATION OF PHARMA 2015 (MENTAL HEALTH EDITION)
- THE PATIENT PERSPECTIVE
- THE PATIENT PERSPECTIVE
|
London, to be published 14th November 2016. This report is based on the findings of a PatientView November 2015-January 2016 survey exploring the views of 209 patient groups with an interest in mental health conditions worldwide. The report provides feedback on the corporate reputation of the pharma industry during 2015, from the perspective of these patient groups, as well as the performance of 20 pharma companies for six key indicators that influence corporate reputation. Results are compared with those attained across all therapy areas in 2015.
The 20 companies analysed:
AbbVie I Actavis I AstraZeneca I Boehringer Ingelheim I Bristol-Myers Squibb I Eli Lilly (Lilly) I GSK I Janssen I Lundbeck I Merck & Co I Novartis I Otsuka I Pfizer I Roche I Sandoz I Sanofi I Servier I Shire I Takeda I Teva To obtain more details about this report click on links on the left | ||
